Conditions: Overactive Bladder
Keywords: Urine proteomics overactive bladder
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 21
Healthy volunteers: yes

Brief summary:
This study is being done to evaluate the use of a new technology (urine proteomics) - the study of proteins in the urine to identify urine markers of overactive bladder (OAB) from a simple voided urine specimen.

Detailed description:
The objectives of the study are:

1. to improve the diagnosis of overactive bladder using a non-invasive technology (urine proteomics) and
2. to study how potential urine biomarkers changes with overactive bladder symptoms after patients have been treated with fesoterodine, an FDA approved drug for the treatment of overactive bladder.

Arms:
arm 1: Females with overactive bladder symptoms will be given Fesoterodine 4 mg. daily for six weeks.

Interventions: intervention 1: fesoterodine
Intervention descriptions: intervention 1: Fesoterodine 4 mg. tablet by mouth daily for six weeks

Protocol document: